BioMed Research International / 2016 / Article / Tab 4

Research Article

Association between the Achievement of Target Range CKD-MBD Markers and Mortality in Prevalent Hemodialysis Patients in Taiwan by Using the Kidney Disease: Improving Global Outcomes Clinical Guidelines

Table 4

Odds ratio of all-cause and CV mortality by achievement of KDIGO clinical guideline, P target.

OR (95% CI)
Model 1Model 2Model 3

P (mg/dL), all-cause
<2.41.61 (0.80~3.22)0.171.16 (0.42~3.17)0.770.89 (0.18~4.35)0.88
2.4~4.71.001.001.00
>4.71.13 (0.82~1.55)0.471.76 (1.19~2.60)0.0041.82 (1.17~2.82)0.007

P (mg/dL), CV
<2.42.13 (0.62~7.31)0.231.78 (0.36~8.88)0.484.70 (0.69~31.9)0.11
2.4~4.71.001.001.00
>4.71.60 (0.86~2.97)0.132.59 (1.27~5.32)0.0092.62 (1.19~5.76)0.01

Logistic regression model:
Model 1: unadjusted.
Model 2: adjusted for age, sex, hemodialysis vintage, etiology of renal failure, EPO, vitamin-D analogs, antihypertensive agent, iron use, and parathyroidectomy.
Model 3: model 2 + baseline laboratory results (albumin, hemoglobin, cholesterol, triglyceride, glucose (fasting), ferritin, Ca, iPTH, potassium, uric acid, urea, and cardiac-thoracic ratio).

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.